Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Accreditation Information

Overcoming Treatment Challenges in the Treatment-Experienced Patient With HIV

ACTIVITY LINKS

This CME activity is provided by OA Education.

This program is sponsored by Medical Education Resources, Inc., a nonprofit medical education organization, and supported through an educational grant from Ortho Biotech and Tibotec Therapeutics.


For Physicians:

Advertisement
Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

Medical Education Resources designates this educational activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This CME activity was planned and produced in accordance with the ACCME Essentials.


For Nurses:

Medical Education Resources is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.8 contact hours (2006) and 1.5 contact hours (2007). Provider approval expires July 31, 2007.

Provider approved by the California Board of Registered Nursing, Provider #CEP 12299, for 1.8 contact hours (2006) and 1.5 contact hours (2007).


For Pharmacists:

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Statements of credit will be mailed within six to eight weeks of receipt of appropriate documentation.

Universal Program Number: 816-000-06-059-H02


Release Date: December 20, 2006.
Expiration Date: December 20, 2007.



Program Information

Overview:

The continued development of new antiretroviral agents has led to significant improvements in how HIV is managed by healthcare providers. Currently, there are more than 25 agents approved for the treatment of HIV infection; however, despite a significant decrease in HIV-related morbidity and mortality, current regimens face increasing problems with drug resistance, cross-resistance between different classes of antiretrovirals, and long-term toxicity. Therefore, in addition to further improving currently available antiretroviral drugs, there is a clear and increasingly urgent need for the development of new drugs that target different aspects of the HIV life cycle to overcome these therapeutic challenges in the treatment-experienced patient with HIV. New therapies, such as non-peptidic protease inhibitors (PIs), new-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry inhibitors, integrase inhibitors, and maturation inhibitors, have the potential to offer significant benefits and overcome the challenges of treating patients with extensive treatment histories or with highly drug-resistant HIV. Of these therapies, the PIs and NNRTIs have realized the most significant development to date. However, treatment-related toxicities continue to represent additional challenges that can significantly affect the patients' overall well-being and possibly interfere with treatment adherence.

Program Goal:

This activity will review novel antiretroviral agents and discuss treatment-related issues in the management of treatment-experienced patient with HIV.

Target Audience:

This activity is designed for physicians, nurses, and pharmacists involved in the clinical care and treatment of patients with HIV.

Learning Objectives:

After participating in this activity, participants should be able to:

  1. Describe the treatment challenges in the treatment-experienced patient with HIV.
  2. Discuss the rationale for the development of new PIs and new-generation NNRTIs in an effort to improve treatment outcomes in the treatment-experienced patient with HIV.
  3. Discuss clinical findings for the use of new PIs and new-generation NNRTIs in the treatment-experienced patient with HIV.
  4. Describe the safety and efficacy of new PIs and new-generation NNRTIs in the treatment-experienced patient with HIV.
  5. List the common toxicities that occur in treatment-experienced patients with HIV.
  6. Identify the components of a successful toxicity management program for treatment-experienced patients with HIV.
  7. Discuss an evidence-based approach to the integration of clinical findings into clinical practices for the management of the treatment-experienced patient with HIV.


Instructions for Credit

Completion of this continuing-education activity should take approximately 1.5 hours. Please follow the steps below to ensure your successful completion of this activity and receipt of credit:

  1. Read through the Program Information and Disclosure Information for this activity.
  2. Read the Required Presentations.
  3. Click on one of the "Take Post-Test" links on this page and enter your login information in the pop-up window that appears.
  4. Enter or confirm the personal information that is required for you to receive credit for successfully completing this activity.
  5. Complete and submit your answers to the post-test for this activity. To pass the post-test, you must answer at least 70% of the questions correctly.
  6. Complete and submit your responses to the course evaluation survey.
  7. Sit back and wait! Your continuing-education certificate will be mailed to you within six to eight weeks after your successful completion of the above steps. To review the results of the post-tests you have taken to date, please refer to your personalized chart on the CME/CE Central main page. If you have any questions, please don't hesitate to contact us at CME@thebodypro.com.


Hardware/Software Requirements:

A standard Web browser, such as Internet Explorer or Firefox, an Internet connection, and Flash 6 player or later are necessary for participation in this activity.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by TheBodyPRO.com.
 

Tools
 

Advertisement